{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:07:37Z","timestamp":1749528457406,"version":"3.41.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Daiichi-Sankyo"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03105-2","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T15:18:05Z","timestamp":1748445485000},"page":"591-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Edoxaban treatment without initial heparin lead-in for acute venous thromboembolism: insight from the COMMAND VTE registry-2"],"prefix":"10.1007","volume":"58","author":[{"given":"Yuta","family":"Tsujisaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuki","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhisa","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moriaki","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Takase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Oi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Otsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Usami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyonori","family":"Togi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norimichi","family":"Koitabashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Hiramori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Doi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Mabuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sueta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shioyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Dohke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koh","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of the COMMAND VTE Registry-2 Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"3105_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jimenez D et al (2020) 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"},{"key":"3105_CR2","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Neumann I, Ageno W, Beyth R, Clark NP, Cuker A, Hutten BA, Jaff MR, Manja V, Schulman S et al (2020) American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4:4693\u20134738. https:\/\/doi.org\/10.1182\/bloodadvances.2020001830","journal-title":"Blood Adv"},{"key":"3105_CR3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","volume":"116","author":"G Agnelli","year":"2007","unstructured":"Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S, Investigators OD-DS (2007) Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59\u20137939): the ODIXa-DVT (oral direct factor Xa inhibitor BAY 59\u20137939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 116:180\u2013187. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.668020","journal-title":"Circulation"},{"key":"3105_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1538-7836.2008.03054.x","volume":"6","author":"WC Botticelli","year":"2008","unstructured":"Botticelli WC, Buller H, Deitchman D, Prins M, Segers A (2008) Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 6:1313\u20131318. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.03054.x","journal-title":"J Thromb Haemost"},{"key":"3105_CR5","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","volume":"112","author":"HR Buller","year":"2008","unstructured":"Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A et al (2008) A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 112:2242\u20132247. https:\/\/doi.org\/10.1182\/blood-2008-05-160143","journal-title":"Blood"},{"key":"3105_CR6","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1056\/NEJMoa064247","volume":"357","author":"I van Gogh","year":"2007","unstructured":"van Gogh I, Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH et al (2007) Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 357:1094\u20131104. https:\/\/doi.org\/10.1056\/NEJMoa064247","journal-title":"N Engl J Med"},{"key":"3105_CR7","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"VTEI Hokusai","year":"2013","unstructured":"Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415. https:\/\/doi.org\/10.1056\/NEJMoa1306638","journal-title":"N Engl J Med"},{"key":"3105_CR8","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1160\/TH10-01-0066","volume":"104","author":"JI Weitz","year":"2010","unstructured":"Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, Kastrissios H, Jin J, Kunitada S (2010) Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 104:633\u2013641. https:\/\/doi.org\/10.1160\/TH10-01-0066","journal-title":"Thromb Haemost"},{"key":"3105_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071711","author":"H Toshima","year":"2020","unstructured":"Toshima H, Hisamatsu A, Kobayashi K, Ishida H, Shimada K (2020) Single-drug approach with edoxaban is effective for resolving non-acute cancer-associated venous thrombosis: a single-arm retrospective analysis. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12071711","journal-title":"Cancers (Basel)."},{"key":"3105_CR10","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2169\/internalmedicine.2524-23","volume":"63","author":"Y Ueno","year":"2024","unstructured":"Ueno Y, Ikeda S, Motokawa T, Honda T, Kurobe M, Akashi R, Yonekura T, Yoshimuta T, Eguchi M, Kawano H et al (2024) Real-world safety and effectiveness of edoxaban in patients with venous thromboembolism with or without preceding parenteral anticoagulants: a single-center retrospective study. Intern Med 63:1845\u20131853. https:\/\/doi.org\/10.2169\/internalmedicine.2524-23","journal-title":"Intern Med"},{"key":"3105_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2023.08.007","volume":"118","author":"K Kaneda","year":"2023","unstructured":"Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N, Kobayashi Y, Ikeda S, Kim K, Inoko M et al (2023) Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. Eur J Intern Med 118:59\u201372. https:\/\/doi.org\/10.1016\/j.ejim.2023.08.007","journal-title":"Eur J Intern Med"},{"key":"3105_CR12","unstructured":"Edoxaban Highlights of Prescribing Information."},{"key":"3105_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"3105_CR14","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v042.i08","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA (2011) MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. https:\/\/doi.org\/10.18637\/jss.v042.i08","journal-title":"J Stat Softw"},{"key":"3105_CR15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/sim.956","volume":"20","author":"TMTAPM Grambsch","year":"2001","unstructured":"Grambsch TMTAPM (2001) Modeling survival data: extending the cox model. Stat Med 20:2053\u20132054. https:\/\/doi.org\/10.1002\/sim.956","journal-title":"Stat Med"},{"key":"3105_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14061120","author":"N Ferri","year":"2022","unstructured":"Ferri N, Colombo E, Tenconi M, Baldessin L, Corsini A (2022) Drug-drug interactions of direct oral anticoagulants (DOACs): from pharmacological to clinical practice. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14061120","journal-title":"Pharmaceutics"},{"key":"3105_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0037-1615251","volume":"2","author":"MPA Brekelmans","year":"2018","unstructured":"Brekelmans MPA, Buller HR, Mercuri MF, Ageno W, Chen CZ, Cohen AT, van Es N, Grosso MA, Medina AP, Raskob G et al (2018) Direct oral anticoagulants for pulmonary embolism: importance of anatomical extent. TH Open 2:e1\u2013e7. https:\/\/doi.org\/10.1055\/s-0037-1615251","journal-title":"TH Open"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03105-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03105-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:02:45Z","timestamp":1749513765000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03105-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["3105"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03105-2","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"25 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Yamashita received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo, and grant support from Bayer Healthcare and Daiichi-Sankyo. Dr. Morimoto reports lecturer\u2019s fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray; manuscript fees from Bristol-Myers Squibb and Kowa; advisory board for Sanofi. Dr. Kaneda received lecture fees from Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Nishimoto received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Ikeda N. received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, and Daiichi-Sankyo. Dr. Ikeda S. received lecture fees from Bayer Healthcare, Bristol-Myers Squibb and Daiichi-Sankyo. Dr. Ogihara received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo, and a research fund from Bayer Healthcare. Dr. Koitabashi received lecture fees from Bayer Healthcare and grant support from Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}